人类呼吸道合胞病毒抑制剂的最新进展  

Recent advances in human respiratory syncytial virus inhibitors

作　　者：吕荣菊[1] 吴清儒 王厚伟[1] LU Rong-ju;WU Qing-ru;WANG Hou-wei(School of Pharmacy,Shandong University of Traditional Chinese Medicine,Jinan 250355,Chin)

机构地区：[1]山东中医药大学药学院,济南250355

出　　处：《中国新药杂志》2018年第14期1612-1618,共7页Chinese Journal of New Drugs

基　　金：山东省高校中医药抗病毒协同创新中心资助项目(XTCX2014B-01);山东省自然科学基金资助项目(ZR2013HM035)

摘　　要：人类呼吸道合胞病毒(hRSV)是婴幼儿下呼吸道感染最常见病因,对易感人群婴幼儿、老年人和免疫受损者健康带来严重影响。目前,临床上常用人源化单克隆抗体和利巴韦林治疗hRSV引发的下呼吸道感染,但由于它们的疗效、成本、气雾给药的安全性、易用性等问题使其临床应用有限。因此,研发新的抗hRSV药物具有迫切需求。为此,本文根据候选药物在病毒复制周期中发挥作用的阶段,从抑制病毒吸附、融合、复制以及抑制病毒转录4个方面综述了hRSV抑制剂的最新进展,为抗hRSV新药研发提供文献依据和新思路。Human respiratory syncytial virus（ hRSV） is the most common cause of lower respiratory tract infection in infants and young children,and has a serious impact on the health of infants,elderly and immunocompromised patients. At present,humanized monoclonal antibodies and ribavirin are commonly used clinically in the treatment of hRSV-induced lower respiratory tract infections,but their clinical application is limited due to the efficacy,cost,and safety and ease of use of aerosol administration. Therefore,the development of new anti-hRSV drugs has an urgent need. In this paper,we reviewed the recent progress of hRSV inhibitors from four aspects： the inhibition of virus adsorption,fusion,replication and viral transcription,according to the stage of the role of candidate drugs in the viral replication cycle,to provide a scientific basis and new ideas for research and development of anti-hRSV new drugs.

关 键 词：人类呼吸道合胞病毒 抑制剂 抗炎 治疗 

分 类 号：R978.7[医药卫生—药品]